Skip to main content
. 2021 Apr 2;100(13):e25223. doi: 10.1097/MD.0000000000025223

Figure 2.

Figure 2

Probability of persistence with golimumab treatment in patients (A) diagnosed with axial SpA (red) or PsA (blue); (B) discontinuing the first anti-TNF drug for loss of efficacy (red) versus for other reasons (blue); (C) whose baseline C-reactive protein (CRP) level was over (red) or under (blue) the median value; (D) whose baseline erythrocyte sedimentation rate (ESR) level was over (red) or under (blue) the median value; (E) treated with adalimumab (red), etanercept (green) or infliximab (blue) as first anti-TNF drug.